Indoleamine 2,3-dioxygenase in melanoma progression and BRAF inhibitor resistance

Autor(es):Mostrar menos -

Sandri, Silvana ^[1] ; Watanabe, Luis R. M. ^[1] ; de Oliveira, Erica Aparecida ^[1] ; Faiao-Flores, Fernanda ^[1] ; Migliorini, Silene ^[1] ; Tiago, Manoela ^[1] ; Felipe-Silva, Aloisio ^[2] ; Vazquez, Vinicius de Lima ^[3] ; Souza, Paola da Costa ^[4] ; Lopes Consolaro, Marcia Edilaine ^[5] ; Campa, Ana ^[1] ; Maria-Engler, Silvya Stuchi ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol Anal, Skin Biol Grp, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med FMUSP, Dept Pathol, Sao Paulo - Brazil

^[3] Barretos Canc Hosp, Inst Res & Educ & Melanoma Sarcoma Surg, Barretos, SP - Brazil

^[4] Lab Souza Patol, Maringa, Parana - Brazil

^[5] Univ Estadual Maringa, Dept Clin Anal & Biomed, Maringa, Parana - Brazil

• Tipo de documento: Artigo Científico
• Fonte: PHARMACOLOGICAL RESEARCH; v. 159, SEP 2020.
• Citações Web of Science: 0

Resumo

Indoleamine 2,3-dioxygenase (IDO) is associated with the progression of many types of tumors, including melanoma. However, there is limited information about IDO modulation on tumor cell itself and the effect of BRAF inhibitor (BRAFi) treatment and resistance. Herein, IDO expression was analyzed in different stages of melanoma development and progression linked to BRAFi resistance. IDO expression was increased in primary and metastatic melanomas from patients' biopsies, especially in the immune cells infiltrate. Using a bioinformatics approach, we also identified an increase in the IDO mRNA in the vertical growth and metastatic phases of melanoma. Using in silico analyses, we found that IDO mRNA was increased in BRAFi resistance. In an in vitro model, IDO expression and activity induced by interferon-gamma (IFN gamma) in sensitive melanoma cells was decreased by BRAFi treatment. However, cells that became resistant to BRAFi presented random IDO expression levels. Also, we identified that treatment with the IDO inhibitor, 1-methyltryptophan (1-MT), was able to reduce clonogenicity for parental and BRAFi-resistant cells. In conclusion, our results support the hypothesis that the decreased IDO expression in tumor cells is one of the many additional outcomes contributing to the therapeutic effects of BRAFi. Still, the IDO production changeability by the BRAFi-resistant cells reiterates the complexity of the response arising from resistance, making it not possible, at this stage, to associate IDO expression in tumor cells with resistance. On the other hand, the maintenance of 1-MT off-target effect endorses its use as an adjuvant treatment of melanoma that has become BRAFi-resistant. (AU)

• Processo FAPESP: 17/04926-6 - Melanoma e quimiorresistência: modelos in vitro e in silico para explorar alvos terapêuticos
• Beneficiário: Silvya Stuchi Maria-Engler
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/26148-5 - O papel de TFEB/3 em resposta à limitação de nutrientes em melanomas MITF positivos e negativos
• Beneficiário: Érica Aparecida de Oliveira
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado
• Processo FAPESP: 12/05910-2 - Avaliação da expressão de RECK e ALX3 em linhagens e amostras de pacientes com melanoma resistentes ao tratamento com vemurafenib (PLX4032)
• Beneficiário: Manoela Tiago dos Santos
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado
• Processo FAPESP: 11/19045-9 - Metilação dos genes RECK e ALX3 em melanoma humano
• Beneficiário: Manoela Tiago dos Santos
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 16/16554-3 - Genes emergentes na progressão e quimiorresistência do melanoma
• Beneficiário: Érica Aparecida de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 13/05172-4 - Impacto das proteínas da Transição epitélio-mesênquima em melanoma quimioresistente ao vemurabenibe
• Beneficiário: Fernanda Faião Flores
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 15/10821-7 - Efeito da inibição de Hsp90 nas vias de escape terapêutico de melanoma BRAF-mutado
• Beneficiário: Fernanda Faião Flores
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Pós-Doutorado